[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.172.174. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
May 11, 2011

Evaluation of Agents to Reduce Infarct SizeIt Can Be Quite REVEALing

Author Affiliations

Author Affiliation: VA Boston Healthcare System, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

JAMA. 2011;305(18):1908-1909. doi:10.1001/jama.2011.600

Reduction of myocardial infarct size remains an important objective in reperfusion therapy. Timely mechanical or pharmacological reperfusion is essential, but beyond that, acute therapies to reduce infarct size and limit reperfusion injury are largely lacking. Erythropoietin had been demonstrated to reduce infarct size in experimental models, although the data are somewhat mixed.18 Therefore, it would seem to be a logical agent to test prospectively in a trial of acute myocardial infarction (MI).9

First Page Preview View Large
First page PDF preview
First page PDF preview
×